
republished from pain news network and reported by youarewithinthenorms.com
NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC.T. SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., MBA., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD , LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS
CVS is facing a new opioid lawsuit from the Department of Justice, alleging that the company knowingly filled unlawful prescriptions and incentivized pharmacists to do so.

CVS strongly denies these allegations, arguing that the government’s standards are vague and inconsistent, and that the prescriptions were written by government-licensed doctors. The lawsuit highlights the difficult position pharmacies are in, facing criticism for both over- and under-prescription of opioids.

CVS points to its efforts to combat opioid misuse and recent court victories rejecting similar claims, suggesting a possible shift in the legal landscape. The article concludes by noting the potentially financially motivated nature of the lawsuits and expressing support for CVS’s defense.
By Crystal Lindell of Pain News Network
CVS Pushes Back Against DOJ’s Latest Opioid Lawsuit
“The U.S. Justice Department’s latest opioid lawsuit against CVS is getting some push back from the pharmacy chain. The DOJ alleges that CVS knowingly filled “unlawful prescriptions” for opioids and other controlled substances, and then sought reimbursement for them from federal healthcare programs like Medicaid and Medicare.

Specifically, the DOJ claims that CVS had “corporate-mandated performance metrics” that incentivized pharmacists to fill the prescriptions. The government also alleges that CVS “set staffing levels far too low” for pharmacists to meet their corporate goals and legal obligations.

“CVS has already agreed to pay about $5 billion to settle opioid litigation. The company says the latest lawsuit, which seeks unspecified additional penalties, is just another cash grab.”

“Our complaint alleges that CVS repeatedly filled controlled substance prescriptions that were unlawful and pressured its pharmacists to fill such prescriptions without taking the time needed to confirm their validity,” Deputy Assistant Attorney General Brian Boynton said in a statement. “The practices alleged contributed to the opioid crisis and opioid-related deaths.”

CVS issued a statement in response to the lawsuit that “strongly disagrees with the allegations and false narrative.” The company said the standards the DOJ is claiming CVS didn’t meet are so vague and ever-changing as to be useless.
“The government’s lawsuit seeks to impose a shifting standard for pharmacy practice,” CVS said. “Many of the litigation theories laid out in the complaint are not found in any statute or regulation, and relate to topics on which the government has declined to provide guidance.

“Each of the prescriptions in question was for an FDA-approved opioid medication prescribed by a practitioner who the government itself licensed, authorized, and empowered to write controlled-substance prescriptions.”
I have to say, it’s good to see CVS defend itself in these situations.
Especially by pointing out the obvious: The prescriptions were written by doctors who were licensed by the government. Although pharmacists have a “corresponding authority” to make sure a prescription is legitimate, why should a private pharmacy chain be held to a higher standard than the government itself?
The government’s lawsuit intensifies a serious dilemma for the pharmacy industry, which is simultaneously second-guessed for dispensing too many opioids and for filling too few.

Over the last few years, it seems like every government agency in existence has been looking for anyone they could possibly sue in relation to opioids. As a result, about $50 billion in opioid settlement money will be paid in coming years by opioid makers, distributors and pharmacies.
However, there’s one glaring aspect of this tactic that makes it clear the lawsuits aren’t about helping people hurt by opioids, but about finding ways for the government and plaintiff law firms to get more money. Much of the settlement money received so far has been earmarked for law enforcement and other government projects that have little to do with opioids.

‘We Will Defend Ourselves’
CVS has already agreed to pay about $5 billion to settle opioid litigation. The company says the latest lawsuit, which seeks unspecified additional penalties, is just another cash grab.
“We will defend ourselves vigorously against this misguided federal lawsuit, which follows on the heels of years of litigation over these issues by state and local governments — claims that already have been largely resolved by a global agreement with the participating state Attorneys General,” the company said.
CVS says it has been an “industry leader” in developing programs to fight opioid misuse. In recent years, the nation’s largest pharmacy chain has refused to fill controlled substance prescriptions written by over 1,250 doctors, about half of whom the government continues to license.
The company also points to its “Our Opioid Response” website, which features a telling headline about government regulations and the scrutiny faced by pharmacists:

“Fill this opioid prescription. No, wait, actually you can’t do that. Or, maybe, you can: The dilemma for community pharmacists.”
The text on the site then goes on to again point out the DEA’s vague guidance and inconsistent stance on the issue.

“Whichever decision they make, community pharmacists know they can – and will – be second-guessed later. Too often, we have seen government agencies and trial lawyers question the good-faith decisions made by pharmacists while a patient waits at the pharmacy counter, often in pain. While simultaneously being accused of dispensing too few opioids and too many, pharmacists and pharmacies face threats of liability no matter their actions,” CVS said.

A recent court case suggests that CVS and other pharmacy chains are making some headway in defending themselves. The Ohio Supreme Court ruled this week that CVS, Walmart and Walgreens are not “public nuisances” under the state’s product liability law. Similar rulings have also been made in West Virginia, California and Oklahoma, rejecting public nuisance claims that resulted in costly opioid settlements.

CVS says it is standing up for “patients enduring relentless pain,” and as a patient who faces relentless pain, I’m happy to see it. While I’m skeptical that the overall tide is turning when it comes to public attitudes about opioids, it’s good to know at least one company is pushing back.”

OR SEND
TO CASH APP:$docnorm
ZELLE 3135103378

ALL WATCHED OVER BY MACHINES OF LOVING GRACE
BE SURE TO DONATE TO THE MARK IBSEN GOFUNDME DEFENSE FUND, WHERE THE SON ALWAYS RISES!!!


FOR NOW, YOU ARE WITHIN
THE NORMS

REFERENCES:
CVS Opioid Lawsuit FAQ
1. What is the basis of the Justice Department’s lawsuit against CVS?
The Department of Justice (DOJ) alleges that CVS knowingly filled unlawful prescriptions for opioids and other controlled substances, seeking reimbursement from federal healthcare programs like Medicaid and Medicare. They claim CVS incentivized pharmacists to fill these prescriptions through corporate-mandated performance metrics and inadequate staffing levels, contributing to the opioid crisis.
2. How does CVS defend itself against these allegations?
CVS argues that the DOJ’s claims are based on vague and shifting standards that lack clear legal grounding. They emphasize that the prescriptions in question were written by government-licensed practitioners, questioning why CVS should be held to a higher standard than the government itself.
3. What is the “dilemma” facing the pharmacy industry in relation to opioids?
The pharmacy industry is caught between accusations of dispensing too many opioids and filling too few. They face scrutiny and potential legal action regardless of their actions, making it difficult to navigate the complex landscape of opioid prescribing and dispensing.
4. What is CVS’s stance on the opioid settlements and lawsuits?
CVS has already agreed to pay approximately $5 billion to settle previous opioid litigation. They view the DOJ’s latest lawsuit as a misguided attempt to extract more money, highlighting that much of the settlement funds have been allocated to projects unrelated to opioid treatment or support.
5. What actions has CVS taken to address opioid misuse?
CVS claims to be an industry leader in combatting opioid misuse. They have refused to fill controlled substance prescriptions from over 1,250 doctors and developed programs to address the issue. Their “Our Opioid Response” website highlights the challenges faced by pharmacists in navigating conflicting regulations and scrutiny.
6. What legal victories has CVS achieved in defending itself against opioid-related claims?
The Ohio Supreme Court ruled that CVS, along with Walmart and Walgreens, are not “public nuisances” under state product liability law, rejecting claims that led to costly settlements. Similar rulings have occurred in West Virginia, California, and Oklahoma.
7. What is the significance of CVS highlighting the DEA’s role in the opioid crisis?
By pointing out the DEA’s vague guidance and inconsistent stance on opioid prescribing, CVS shifts some responsibility to the government agency tasked with regulating controlled substances. They argue that pharmacists are unfairly penalized for following the prescriptions of DEA-licensed practitioners.
8. What is the author’s perspective on CVS’s response to the lawsuit and the broader opioid litigation landscape?
The author expresses support for CVS’s defense against the lawsuit, particularly their emphasis on the government’s role in licensing prescribers. While acknowledging the ongoing challenges related to opioids, the author views CVS’s pushback as a positive step in holding all stakeholders accountable.

CVS and the Opioid Crisis
Timeline of Events:
Unknown Date (Recent Years):
- Government agencies begin targeting various entities within the opioid industry with lawsuits.
- CVS implements programs to combat opioid misuse, including refusing to fill prescriptions from over 1,250 doctors.
- CVS launches the “Our Opioid Response” website, highlighting pharmacists’ dilemmas regarding opioid dispensing.
Unknown Date (Before December 20, 2024):
- Multiple states (including Ohio, West Virginia, California, and Oklahoma) reject public nuisance claims against pharmacy chains in opioid litigation, offering some legal victories for pharmacies.
- CVS agrees to pay approximately $5 billion to settle previous opioid litigation.
December 20, 2024:
- The U.S. Justice Department files a new lawsuit against CVS, alleging the pharmacy chain knowingly filled unlawful opioid prescriptions and sought reimbursement from federal healthcare programs.
- The DOJ claims CVS incentivized pharmacists to fill these prescriptions through performance metrics and inadequate staffing levels.
- CVS issues a statement strongly disagreeing with the DOJ’s allegations, arguing that the government’s standards are vague and shifting.
- CVS defends itself by emphasizing that all prescriptions were written by government-licensed doctors.
Future:

- Approximately $50 billion in opioid settlement money will be paid by opioid manufacturers, distributors, and pharmacies over the coming years.
Cast of Characters:
1. CVS: The largest pharmacy chain in the United States, facing multiple lawsuits related to opioid dispensing practices.
- Bio: CVS has been a key player in the opioid crisis, dispensing large volumes of opioid medications. They have implemented programs to combat opioid misuse but remain a target for government lawsuits seeking financial penalties.
2. U.S. Justice Department (DOJ): The federal agency responsible for enforcing federal laws, currently pursuing legal action against CVS and other entities involved in the opioid crisis.
- Bio: The DOJ is actively pursuing financial settlements from various players in the opioid industry, aiming to hold them accountable for their role in the crisis. They argue that companies like CVS contributed to the problem by filling unlawful prescriptions.
3. Brian Boynton: Deputy Assistant Attorney General at the DOJ, leading the latest lawsuit against CVS.
- Bio: Boynton is a key figure in the government’s legal efforts against CVS, publicly criticizing the company’s practices and emphasizing the potential link to opioid-related deaths.
4. Crystal Lindell: Author of the Pain News Network article and advocate for chronic pain patients.
- Bio: Lindell expresses sympathy for CVS’s position and criticizes the government’s approach, suggesting that lawsuits are motivated by financial gain rather than genuine concern for those affected by the opioid crisis.
5. State Attorneys General: Representatives of various states involved in previous opioid litigation that led to settlements with CVS and other companies.
- Bio: State Attorneys General have been actively pursuing legal action against the opioid industry, seeking compensation for the costs associated with the crisis within their respective states.
6. Doctors (Physicians): Healthcare professionals responsible for prescribing opioid medications.
- Bio: While not directly named, doctors play a central role in the opioid crisis as the prescribers of these medications. CVS argues that they should be held accountable, as they are licensed by the government and ultimately responsible for the prescriptions they write.
7. Pharmacists: Healthcare professionals responsible for dispensing medications, including opioids, facing pressure from both government regulations and corporate performance metrics.
- Bio: Pharmacists are caught in a difficult position, facing scrutiny for both over-dispensing and under-dispensing opioids. They are tasked with balancing patient needs with legal obligations and ethical considerations.
8. Patients with Chronic Pain: Individuals suffering from pain who rely on opioid medications for pain management.
- Bio: This group is often overlooked in the legal battles surrounding opioids. Lindell highlights their perspective, emphasizing the need for access to pain relief while acknowledging the risks associated with opioid use.
